| Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (NCT05437679) | Angle plc | 2022-07-05 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors (NCT05256381) | SOTIO Biotech AG | 2022-06-21 |
| Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer (NCT05081193) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2022-03-07 |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients (NCT06193993) | National University Hospital, Singapore | 2021-11-30 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours (NCT05057013) | Cancer Research UK | 2021-11-10 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors (NCT05084859) | Biosplice Therapeutics, Inc. | 2021-11-03 |
| Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04781374) | Beth Israel Deaconess Medical Center | 2021-05-21 |
| HRR Prevalence in LatAm PROSPECT Study (NCT04962880) | AstraZeneca | 2021-04-21 |
| HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT03850795) | Hinova Pharmaceuticals USA, Inc. | 2021-03-15 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC (NCT05549778) | Jiangnan University | 2021-01-06 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (NCT04541225) | Nuvation Bio Inc. | 2020-12-08 |
| Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) (NCT04070209) | Sir Mortimer B. Davis - Jewish General Hospital | 2020-10-19 |
| Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (NCT04549207) | Ottawa Hospital Research Institute | 2020-10-09 |
| Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma (NCT04567875) | Ospedale Andrea Tortora di Pagani | 2020-07-16 |
| Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial (NCT05188911) | Fudan University | 2020-07-15 |
| Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone (NCT04232761) | Bayer | 2020-07-07 |
| Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone (NCT06321679) | European Institute of Oncology | 2020-07-03 |
| Metastasis-directed Therapy in Castration-refractory Prostate Cancer (NCT04222634) | Universitaire Ziekenhuizen KU Leuven | 2019-12-27 |
| Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO (NCT03934164) | Institute of Cancer Research, United Kingdom | 2019-11-28 |
| Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (NCT03569280) | Kangpu Biopharmaceuticals, Ltd. | 2019-11-26 |
| A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer (NCT04148885) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2019-11-01 |
| pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer (NCT04090528) | University of Wisconsin, Madison | 2019-10-21 |
| Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide (NCT03700099) | Instituto do Cancer do Estado de São Paulo | 2019-09-03 |
| ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer (NCT04028388) | Modra Pharmaceuticals | 2019-07-17 |
| A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer (NCT04019327) | Memorial Sloan Kettering Cancer Center | 2019-07-11 |
| I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). (NCT03939689) | Progenics Pharmaceuticals, Inc. | 2019-05-30 |
| Safety and Pharmacokinetics of ODM-209 (NCT03878823) | Orion Corporation, Orion Pharma | 2019-04-17 |
| A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC (NCT04102124) | Jiangsu HengRui Medicine Co., Ltd. | 2019-04-08 |
| Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients (NCT03601143) | Technical University of Munich | 2019-03-01 |
| Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial (NCT03658486) | Queen's University, Belfast | 2019-02-19 |
| Testosterone Therapy in Castration Resistant Prostate Cancer (NCT03734653) | University of Colorado, Denver | 2019-01-18 |
| Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. (NCT03869762) | Cancer Trials Ireland | 2019-01-09 |
| VAccination in Early and ADvanced Prostate caNCEr (NCT03815942) | University of Oxford | 2018-12-10 |
| Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (NCT03506997) | Institute of Cancer Research, United Kingdom | 2018-11-27 |
| A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC (NCT03741712) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-20 |
| Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic (NCT03101046) | UNICANCER | 2018-11-15 |
| Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway (NCT03652493) | Centre Francois Baclesse | 2018-09-10 |
| COMbination of Bipolar Androgen Therapy and Nivolumab (NCT03554317) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-09-05 |
| Selective Treatment According to Molecular Subtype of Prostate Cancer (NCT03696186) | Tianjin Medical University Second Hospital | 2018-08-01 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer (NCT03514836) | SOTIO a.s. | 2018-05-23 |
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) (NCT03473925) | Merck Sharp & Dohme LLC | 2018-04-10 |
| Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients (NCT03526562) | University Hospital, Ghent | 2018-01-15 |
| Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer (NCT03960788) | University of Cincinnati | 2018-01-02 |
| Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer (NCT03927287) | Rabin Medical Center | 2018-01-01 |
| CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy (NCT03356912) | Consorzio Oncotech | 2017-11-22 |
| Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate (NCT03356444) | West China Hospital | 2017-11-01 |
| The Combination Therapy With Ra-223 and Enzalutamide (NCT03305224) | Taro Iguchi, MD, PHD | 2017-10-27 |
| Bone Marrow Suppression and Recovery During Radionuclide Treatment (NCT03247010) | Rigshospitalet, Denmark | 2017-06-20 |
| Predictive Nomogram of CRPC (NCT03177551) | Tianjin Medical University Second Hospital | 2017-05-04 |
| Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer (NCT03672396) | UNC Lineberger Comprehensive Cancer Center | 2017-04-01 |
| Oral Calcitriol With Ketoconazole in CRPC (NCT03261336) | Donald Trump, MD | 2017-01-06 |
| Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer (NCT04838899) | Sunnybrook Health Sciences Centre | 2016-07-16 |
| Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer (NCT02833883) | Memorial Sloan Kettering Cancer Center | 2016-07-01 |
| Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (NCT02429193) | University Health Network, Toronto | 2016-03-01 |
| A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) (NCT02384382) | Pfizer | 2015-11-30 |
| Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC (NCT02502994) | Norio Nonomura | 2015-05-01 |
| A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer (NCT02346526) | Massachusetts General Hospital | 2015-04-01 |
| Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (NCT02380274) | Astellas Pharma Global Development, Inc. | 2015-03-27 |
| CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. (NCT03381326) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2014-12-15 |
| Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. (NCT02346578) | Taro Iguchi, MD, PHD | 2014-12-01 |
| Long-Term Specified Drug Use-Results Survey for Xtandi Capsule (NCT02669771) | Astellas Pharma Inc | 2014-11-30 |
| A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy (NCT02124668) | Astellas Pharma Europe B.V. | 2014-09-23 |
| Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (NCT02207504) | Dana-Farber Cancer Institute | 2014-08-01 |
| Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) (NCT02054793) | Emmanuel Antonarakis, MD | 2014-06-01 |
| A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer (NCT02361086) | Innocrin Pharmaceutical | 2014-06-01 |
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC (NCT01995058) | Exelixis | 2014-02-01 |
| Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer (NCT02025010) | Dana-Farber Cancer Institute | 2014-01-27 |
| A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (NCT02066961) | Astellas Pharma Global Development, Inc. | 2013-12-31 |
| F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer (NCT01981707) | University Hospital, Grenoble | 2013-12-01 |
| Cabozantinib in Men With Castration-Resistant Prostate Cancer (NCT01703065) | University of Washington | 2013-06-18 |
| A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (NCT01637402) | Terence Friedlander, MD | 2013-03-13 |
| Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer (NCT01646684) | Novartis Pharmaceuticals | 2013-03-08 |
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients (NCT01634061) | Novartis Pharmaceuticals | 2012-09-01 |
| Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (NCT01605227) | Exelixis | 2012-07-01 |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (NCT01522443) | Exelixis | 2012-03-01 |
| Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (NCT01981109) | Dendreon | 2012-01-01 |
| A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer (NCT02012920) | Innocrin Pharmaceutical | 2011-12-01 |
| Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer (NCT01487863) | Dendreon | 2011-12-01 |
| A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer (NCT07161778) | Barts & The London NHS Trust | 2011-10-19 |
| Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer (NCT01338831) | Novartis Pharmaceuticals | 2011-09-01 |
| Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer (NCT01540071) | Io Therapeutics | 2011-08-01 |
| OGX-427 in Castration Resistant Prostate Cancer Patients (NCT01120470) | British Columbia Cancer Agency | 2010-09-01 |
| A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) (NCT01106352) | Bayer | 2010-07-01 |
| The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer (NCT01487902) | Asan Medical Center | 2010-07-01 |